Table 5.

Differences between CD19- and CD27-positive B-cell monitoring in the whole cohort

	CD19 monitoring	CD 27 monitoring	p value
Follow-up time, years (range)	3.53 (1.21–5.85)	1.41 (1.21–1.62)	< 0.001
Interdose time, months (range)	8.80 (5.78–14.23)	15.93 (8.56–35.37)	< 0.001
Relapse, n	1	1	n.s.
ARR during B-cell monitoring (SD)	0.02 (0.11)	0.03 (0.13)	n.s.
EDSS (range)	2.5 (1–7.5)	2.5 (1–7.5)	n.s.
AEs, n	0	0	n.s.

Follow-up time, interdose time, and EDSS are expressed as median and range; ARR is expressed as mean and SD

ARR annualized relapse rate, EDSS Expanded Disability Status Scale, AEs severe adverse events, n.s. not significant